121 related articles for article (PubMed ID: 25894376)
1. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.
Fan L; Li W; Ying S; Shi L; Wang Z; Chen G; Ye H; Wu X; Wu J; Liang G; Li X
Tumour Biol; 2015 Sep; 36(9):7233-41. PubMed ID: 25894376
[TBL] [Abstract][Full Text] [Related]
2. The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo.
Yu Y; Gao S; Li Q; Wang C; Lai X; Chen X; Wang R; Di J; Li T; Wang W; Wu X
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1321-8. PubMed ID: 22481251
[TBL] [Abstract][Full Text] [Related]
3. Peptidomimetic suppresses proliferation and invasion of gastric cancer cells by fibroblast growth factor 2 signaling cascade blockage.
Li W; Du X; Chen Q; Kang Y; Xu C; Fan L; Ye H; Ying S; Shi L; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2016 Mar; 27(3):164-72. PubMed ID: 26556626
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of a short peptide on p53-null SKOV3 ovarian cancer cells.
Huang YS; Wang TX; Lin XM; Wang H; Li RZ; Zeng X; Zhu C; Chen LK; Guo Q; Liu H; Wu XP
Anticancer Drugs; 2019 Nov; 30(10):973-982. PubMed ID: 31503014
[TBL] [Abstract][Full Text] [Related]
5. A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.
Fan L; Xie H; Chen L; Ye H; Ying S; Wang C; Wu X; Li W; Wu J; Liang G; Li X
Tumour Biol; 2014 Oct; 35(10):10571-9. PubMed ID: 25062723
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.
Gupta AA; Chou RH; Li H; Yang LW; Yu C
Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890
[TBL] [Abstract][Full Text] [Related]
7. Affinity Selection of FGF2-Binding Heparan Sulfates for Ex Vivo Expansion of Human Mesenchymal Stem Cells.
Wijesinghe SJ; Ling L; Murali S; Qing YH; Hinkley SF; Carnachan SM; Bell TJ; Swaminathan K; Hui JH; van Wijnen AJ; Nurcombe V; Cool SM
J Cell Physiol; 2017 Mar; 232(3):566-575. PubMed ID: 27291835
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
Ying S; Du X; Fu W; Yun D; Chen L; Cai Y; Xu Q; Wu J; Li W; Liang G
Eur J Med Chem; 2017 Feb; 127():885-899. PubMed ID: 27829519
[TBL] [Abstract][Full Text] [Related]
9. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
10. FGF2 regulates proliferation, migration, and invasion of ECA109 cells through PI3K/Akt signalling pathway in vitro.
Shi H; Xu J; Zhao R; Wu H; Gu L; Chen Y
Cell Biol Int; 2016 May; 40(5):524-33. PubMed ID: 26833879
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer.
Xu C; Li W; Qiu P; Xia Y; Du X; Wang F; Shen L; Chen Q; Zhao Y; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2015 Apr; 26(4):379-87. PubMed ID: 25521558
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene.
Jian B; Li Z; Xiao D; He G; Bai L; Yang Q
Tumour Biol; 2016 Jul; 37(7):8941-9. PubMed ID: 26753960
[TBL] [Abstract][Full Text] [Related]
13. Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2.
Safran M; Eisenstein M; Aviezer D; Yayon A
Biochem J; 2000 Jan; 345 Pt 1(Pt 1):107-13. PubMed ID: 10600645
[TBL] [Abstract][Full Text] [Related]
14. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
15. A novel bFGF antagonist peptide inhibits breast cancer cell growth.
Li Q; Gao S; Yu Y; Wang W; Chen X; Wang R; Li T; Wang C; Li X; Wu X
Mol Med Rep; 2012 Jul; 6(1):210-4. PubMed ID: 22576745
[TBL] [Abstract][Full Text] [Related]
16. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.
Lefèvre G; Babchia N; Calipel A; Mouriaux F; Faussat AM; Mrzyk S; Mascarelli F
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1047-57. PubMed ID: 19029025
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of inhibitory effect of P7 on 3T3 cell proliferation induced by basic fibroblast growth factor].
Wang C; Lin SQ; Li XK; Wu XP
Yao Xue Xue Bao; 2010 Mar; 45(3):314-7. PubMed ID: 21351506
[TBL] [Abstract][Full Text] [Related]
18. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44.
Hibino S; Shibuya M; Hoffman MP; Engbring JA; Hossain R; Mochizuki M; Kudoh S; Nomizu M; Kleinman HK
Cancer Res; 2005 Nov; 65(22):10494-501. PubMed ID: 16288042
[TBL] [Abstract][Full Text] [Related]
19. Interaction of clodronate with fibroblast growth factor 2 reduces FGF2-activity in endothelial cells.
Rose K; Finger IE; Ferenz KB
Biomed Pharmacother; 2011 Feb; 65(1):46-51. PubMed ID: 21177067
[TBL] [Abstract][Full Text] [Related]
20. FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells.
Sun C; Fukui H; Hara K; Zhang X; Kitayama Y; Eda H; Tomita T; Oshima T; Kikuchi S; Watari J; Sasako M; Miwa H
BMC Cancer; 2015 Apr; 15():333. PubMed ID: 25925261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
